Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

309

Participants

Timeline

Start Date

January 29, 2021

Primary Completion Date

August 19, 2025

Study Completion Date

August 19, 2025

Conditions
Breast Screening
Interventions
OTHER

Clinical Breast exam (CBE)

The standard CBE will be performed by a nurse practitioner (NP) who will record any positive CBE finding.

DEVICE

iBreastExam device

The iBE is an FDA 510(k) cleared portable device which utilizes an array of dynamic capacitive pressure sensors to perform electronic palpation for breast abnormalities. The iBE exam will be administered by a mammogram technologist, blinded to CBE results.

DIAGNOSTIC_TEST

mammogram

All patients will have routine standard mammographic views performed. Patients with positive iBE and/or CBE findings will have additional mammographic and/or ultrasound imaging to determine if a correlating breast lesion is present using the same standard of care algorithm as is used currently for positive CBE findings.

Trial Locations (2)

10035

MSK at Ralph Lauren (All Protocol Activities), New York

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

All Listed Sponsors
collaborator

UE LifeSciences Inc.

INDUSTRY

collaborator

Earlier.org

UNKNOWN

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT04761055 - Study of iBreast, a Handheld Device to Detect Breast Abnormalities During Screening Visits for Breast Cancer | Biotech Hunter | Biotech Hunter